新型口服抗凝药(NOAC) 在心脑血管血栓疾病的防治中发挥了重要作用. 由于参与NOAC
体内过程的转运体和代谢酶的基因多态性, 不同个体口服相同剂量的NOAC 后 …

新型口服抗凝药(NOAC) 达比加群酯, 利伐沙班, 阿哌沙班和依度沙班因其疗效确切, 安全性较优,
被广泛应用于临床抗凝. NOAC 的药代动力学参数和药物反应存在较大的个体间差异 …

Novel oral anticoagulants (NOACs) are becoming a therapy of choice in everyday clinical
practice after almost 50 years during which warfarin and related coumarin derivatives were …

口服抗凝药物在血栓栓塞性疾病的预防和治疗中发挥着重要的作用. 传统的口服抗凝药华法林,
因其治疗窗窄, 需频繁监测而调整剂量等局限性, 在临床使用过程中受到一定的限制 …

Dabigatran, rivaroxaban, apixaban, and edoxaban are direct oral anticoagulants (DOACs)
that are increasingly used worldwide. Taking into account their widespread use for the …

For more than 50 years, oral vitamin K antagonists were the choice of anticoagulant for the
long-term treatment and prevention of arterial and venous thromboembolic events. In recent …

Introduction: The inclusion of pharmacogenetics alongside clinical information in
anticoagulant therapy offers the opportunity for a tailored approach to treatment according to …

Oral anticoagulants play an important role in the prevention and treatment of
thromboembolic diseases. Warfarin, a traditional oral anticoagulant, is limited in clinical use …

The use of oral anticoagulants (OA) is problematic due to its association with hemorrhagic
complications. OA metabolism relies on the CYP2C9 complex. Genetic variations …

Purpose There is growing interest in the use of pharmacogenomics to optimize the safety
and efficacy of anticoagulation therapy. While the pharmacogenomics of warfarin have been …